Tags

Type your tag names separated by a space and hit enter

Recognition and treatment of menstrual migraine.
Neurologist. 2007 Jul; 13(4):197-204.N

Abstract

BACKGROUND

Menstrual migraine is a chronic disorder affecting approximately 12.6 million women in the United States. In spite of its widespread prevalence, menstrual migraine often goes undiagnosed.

REVIEW SUMMARY

Characteristics of menstrual migraine, which include functional disability, increased headache severity, and lack of aura, are often overlooked, and therefore menstrual migraine is often underdiagnosed. Use of a 3-month diary to record migraine patterns can reveal the predictable patterns associated with menstrual migraine, and a diary is demonstrated to be a useful tool in diagnosis. Optimal treatment of menstrual migraine takes advantage of the predictability of the disorder. Treatment alternatives for menstrual migraine include acute therapy and short- or long-term preventive therapies. Acute therapy is given shortly after the migraine begins. Short-term preventive therapies are effective when administered during the time that menstrual migraine is most likely to occur; the treatment window is typically 2 days prior up to 3 days after the onset of menstruation. Providing triptans, nonsteroidal anti-inflammatory drugs, or estrogen supplements (gel or patches) during this window has been demonstrated to provide effective protection during the days when patients are at greatest risk for menstrual migraine. Alternatively, long-term preventive therapy may be required for recurrent headaches in patients with concomitant medical conditions for whom migraine therapy could serve a dual purpose.

CONCLUSION

By recognizing the patterns associated with menstrual migraine, prompt, acute, or preventive therapy can be used to effectively manage the disorder and reduce its related disability.

Authors+Show Affiliations

Albert Einstein College of Medicine, Bronx, New York, USA. clay@chpnet.orgNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17622911

Citation

Lay, Christine L., and Richard Payne. "Recognition and Treatment of Menstrual Migraine." The Neurologist, vol. 13, no. 4, 2007, pp. 197-204.
Lay CL, Payne R. Recognition and treatment of menstrual migraine. Neurologist. 2007;13(4):197-204.
Lay, C. L., & Payne, R. (2007). Recognition and treatment of menstrual migraine. The Neurologist, 13(4), 197-204.
Lay CL, Payne R. Recognition and Treatment of Menstrual Migraine. Neurologist. 2007;13(4):197-204. PubMed PMID: 17622911.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recognition and treatment of menstrual migraine. AU - Lay,Christine L, AU - Payne,Richard, PY - 2007/7/12/pubmed PY - 2007/9/27/medline PY - 2007/7/12/entrez SP - 197 EP - 204 JF - The neurologist JO - Neurologist VL - 13 IS - 4 N2 - BACKGROUND: Menstrual migraine is a chronic disorder affecting approximately 12.6 million women in the United States. In spite of its widespread prevalence, menstrual migraine often goes undiagnosed. REVIEW SUMMARY: Characteristics of menstrual migraine, which include functional disability, increased headache severity, and lack of aura, are often overlooked, and therefore menstrual migraine is often underdiagnosed. Use of a 3-month diary to record migraine patterns can reveal the predictable patterns associated with menstrual migraine, and a diary is demonstrated to be a useful tool in diagnosis. Optimal treatment of menstrual migraine takes advantage of the predictability of the disorder. Treatment alternatives for menstrual migraine include acute therapy and short- or long-term preventive therapies. Acute therapy is given shortly after the migraine begins. Short-term preventive therapies are effective when administered during the time that menstrual migraine is most likely to occur; the treatment window is typically 2 days prior up to 3 days after the onset of menstruation. Providing triptans, nonsteroidal anti-inflammatory drugs, or estrogen supplements (gel or patches) during this window has been demonstrated to provide effective protection during the days when patients are at greatest risk for menstrual migraine. Alternatively, long-term preventive therapy may be required for recurrent headaches in patients with concomitant medical conditions for whom migraine therapy could serve a dual purpose. CONCLUSION: By recognizing the patterns associated with menstrual migraine, prompt, acute, or preventive therapy can be used to effectively manage the disorder and reduce its related disability. SN - 1074-7931 UR - https://www.unboundmedicine.com/medline/citation/17622911/Recognition_and_treatment_of_menstrual_migraine_ L2 - https://doi.org/10.1097/NRL.0b013e31805c746f DB - PRIME DP - Unbound Medicine ER -